glp 1 rheumatoid arthritis glp-1 and Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence future directions Are GLP-1 Medications Helpful for – Glucagon-like Peptide-1 Receptor Agonists in

Clinical Review of How Glucagon-Like Peptide-1 Agonist Obesity Medications Decrease Sexual Desire, and a Biopsychosocial Model for Why We Dont See It

Abbreviations BBB: Bloodbrain barrier CFS: Chronic fatigue syndrome CNS: Central nervous system CoA: Coenzyme A COVID-19: Coronavirus disease 2019 CrAT: Carnitine acetyltransferase CRP: C-reactive protein HPA: Hypothalamicpituitaryadrenal IDO: Indoleamine 2,3-dioxygenase IL-2: Interleukin-2 IMD: Immunometabolic depression MDD: Major depressive disorder ME: Myalgic encephalomyelitis mGluR2: Metabotropic glutamate receptor 2 MS: Multiple sclerosis NMDA: N -Methyl-d-aspartate NMR: Nuclear magnetic resonance Nrf2: Nuclear factor erythroid 2-related factor 2 OCTN2: Organic cation novel type 2 transporter OCT1: Organic cation transporter 1 PAIS: Post-acute infection syndromes PASC: Post-acute sequelae of SARS-CoV-2 infection PDC: Pyruvate dehydrogenase complex PGD2S: Prostaglandin D2 synthase gene QUIN: Quinolinic acid ROS: Reactive oxygen species Trp: Tryptophan TCA: Tricarboxylic acid HO-1: Heme oxygenase 1 PUFAs: Polyunsaturated fatty acids CACT: Carnitine-acylcarnitine translocase MRI: Magnetic resonance imaging [ 18 F]FDG-PET/CT: [ 18 F]Fluorodeoxyglucose positron emission tomography/computed tomography References Abraham NG, Kappas A (2008) Pharmacological and clinical aspects of heme oxygenase

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41

Cancer Epidemiology, Biomarkers & Prevention